Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
(2020) Pharmaceutics — Vol. 12, n° 2, p. 194 [1-15] (2020)
Files
2020_Roex_Pharmaceutics.pdf
Open Access - Adobe PDF
- 628.82 KB
Details
- Authors
Roex, Gils 
Beguin, Yves
- Abstract
- Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
- Affiliations
Citations
Roex, G., Feys, T., Beguin, Y., Kerre, T., Poire, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2020). Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 12(2), 194 [1-15]. https://doi.org/10.3390/pharmaceutics12020194 (Original work published 2020)